NEW YORK (GenomeWeb News) – SuperGen said today that it will screen epigenetic targets for cancer drugs for GlaxoSmithKline, under an agreement announced today.
The Dublin, Calif.-based drug screening and development firm said that it will receive $5 million up front, which includes a $3 million investment from the UK drug maker. It also said that milestone and royalty payments from GSK for development and commercialization could potentially surpass $375 million, and it could also receive tiered royalties reaching double-digits on products derived from the collaboration.
SuperGen will use its CLIMB technology, which merges screening of compound libraries with systems biology to identify drug leads that bind to target proteins, to develop candidates through to early clinical proof of concept.
GlaxoSmithKline will have the option to develop and commercialize products globally derived from those candidates, SuperGen said.